ATE495255T1 - Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs - Google Patents

Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs

Info

Publication number
ATE495255T1
ATE495255T1 AT99942154T AT99942154T ATE495255T1 AT E495255 T1 ATE495255 T1 AT E495255T1 AT 99942154 T AT99942154 T AT 99942154T AT 99942154 T AT99942154 T AT 99942154T AT E495255 T1 ATE495255 T1 AT E495255T1
Authority
AT
Austria
Prior art keywords
scary
phenotype
gene
mouse
leads
Prior art date
Application number
AT99942154T
Other languages
English (en)
Inventor
Mary Brunkow
Eric Jeffery
Kathryn Hjerrild
Fred Ramsdell
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE495255T1 publication Critical patent/ATE495255T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99942154T 1998-08-11 1999-08-11 Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs ATE495255T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9619598P 1998-08-11 1998-08-11
PCT/US1999/018407 WO2000009693A2 (en) 1998-08-11 1999-08-11 Identification of the gene causing the mouse scurfy phenotype and its human ortholog

Publications (1)

Publication Number Publication Date
ATE495255T1 true ATE495255T1 (de) 2011-01-15

Family

ID=22256264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942154T ATE495255T1 (de) 1998-08-11 1999-08-11 Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs

Country Status (8)

Country Link
US (9) US6414129B1 (de)
EP (1) EP1105479B1 (de)
JP (4) JP4351807B2 (de)
AT (1) ATE495255T1 (de)
AU (1) AU5559499A (de)
CA (1) CA2339409A1 (de)
DE (1) DE69943129D1 (de)
WO (1) WO2000009693A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019026A1 (en) * 1995-06-05 2002-02-14 Daniel R. Soppet Human g-protein receptor hgber32
AU5559499A (en) * 1998-08-11 2000-03-06 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
WO2002016656A2 (en) * 2000-08-21 2002-02-28 Celltech R & D, Inc. Methods for detecting mutations in the human scurfy/foxp3 gene
ATE405586T1 (de) * 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
EP2064350B1 (de) * 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression von foxp3 durch krebszellen
WO2008134524A2 (en) * 2007-04-25 2008-11-06 The Children's Hospital Of Philadelphia Compositions and methods for regulating t-cell activity
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
EP2612271A4 (de) 2010-08-31 2017-07-19 Annai Systems Inc. Verfahren und systeme zur bearbeitung von polymersequenzdaten und zugehörigen informationen
US20120232874A1 (en) * 2011-03-09 2012-09-13 Annai Systems, Inc. Biological data networks and methods therefor
WO2013192631A1 (en) 2012-06-22 2013-12-27 Maltbie Dan System and method for secure, high-speed transfer of very large files
ES2665543B1 (es) 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos
CN112004924A (zh) 2018-04-18 2020-11-27 Ucl商务有限公司 增强treg细胞抑制特性的方法
CA3168089A1 (en) * 2020-02-13 2021-08-19 Rosa Bacchetta Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
JP2001519666A (ja) * 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
GB9721909D0 (en) 1997-10-17 1997-12-17 Cantab Pharma Res Gene delivery vectors and their uses
AU758541B2 (en) 1997-10-21 2003-03-27 Targeted Genetics Corporation Amplifiable adeno-associated virus (AAV) packaging cassettes for the production of recombinant AAV vectors
JP2001520047A (ja) 1997-10-21 2001-10-30 ターゲテッド ジェネティックス コーポレイション 組換えａａｖベクターと共に使用するための転写活性化された逆方向末端反復（ｉｔｒ）
AU5559499A (en) * 1998-08-11 2000-03-06 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
ATE405586T1 (de) * 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins

Also Published As

Publication number Publication date
US20050106601A1 (en) 2005-05-19
AU5559499A (en) 2000-03-06
US6683171B1 (en) 2004-01-27
JP2009039099A (ja) 2009-02-26
CA2339409A1 (en) 2000-02-24
DE69943129D1 (de) 2011-02-24
EP1105479A2 (de) 2001-06-13
US20080131411A1 (en) 2008-06-05
US6794145B1 (en) 2004-09-21
US20020168736A1 (en) 2002-11-14
US6683160B1 (en) 2004-01-27
US6667162B1 (en) 2003-12-23
JP2012191949A (ja) 2012-10-11
US6414129B1 (en) 2002-07-02
JP2010029204A (ja) 2010-02-12
WO2000009693A3 (en) 2000-06-15
EP1105479B1 (de) 2011-01-12
US7135612B2 (en) 2006-11-14
JP2002538764A (ja) 2002-11-19
JP4351807B2 (ja) 2009-10-28
US7220579B2 (en) 2007-05-22
US6884618B2 (en) 2005-04-26
WO2000009693A2 (en) 2000-02-24
US20050164247A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
DE69943129D1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
NO20101157L (no) FAD4, FAD5, FAD5-2 og FAD6, nye fettsyredesaturase familiemedlemmer og anvendelser derav
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
BRPI0411182A (pt) método para aumentar a toleráncia de uma planta ao estresse abiótico, método para aumentar a biomassa de uma planta, construto de ácido nucléico, polipeptìdio isolado e célula de planta
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
DE69829857D1 (de) Hypoxie-regulierte gene
EP1509251A4 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
IL159966A0 (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
WO1999027098A3 (en) A-33 related antigens and their pharmacological uses
DK1364023T3 (da) Gener, de udtrykkes i höje niveauer i bruskvæv
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
NZ307444A (en) Polyphenol oxidase genes from lettuce and banana
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DE69031803D1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
DK0904356T3 (da) Aspergillus Oryzae 5-aminolevulinsyre-synthaser og nukleinsyrer, der koder disse
NO20025146L (no) Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav
BR0014926A (pt) Sistema de produção de proteìna
DE69632963D1 (de) Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung
WO1996029407A3 (en) Cellubrevin homologs
DE69738433D1 (de) Rezeptor-tyrosine-kinase gene
EP1475388A3 (de) Neue Untereinheiten eines kalzium-sensitiven Kaliumkanals
ATE298348T1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties